AstraZeneca, Daiichi Sankyo Win EU CHMP Nod for Enhertu in HER2 Tumors

Why It Matters

The CHMP’s positive opinion signals a rapid expansion of antibody‑drug conjugates into new tumor types, reinforcing the therapeutic relevance of HER2 as a target beyond breast cancer. By extending Enhertu’s label, European patients gain access to a treatment that has shown durable responses where conventional options are limited, potentially improving survival outcomes. For the biotech sector, the decision illustrates how robust early‑phase data can accelerate regulatory pathways, encouraging companies to pursue multi‑indication strategies for high‑value biologics. The move also pressures rivals to advance their own ADC pipelines, intensifying R&D investment in linker technologies and payload optimization.

Key Takeaways

• CHMP issued a positive opinion for Enhertu in HER2‑positive solid tumours after prior therapy.
• Decision based on subgroup analyses from Phase II DESTINY‑PanTumor02, DESTINY‑Lung01 and DESTINY‑CRC02 trials.
• Enhertu already approved for breast, lung, gastric and select solid tumours in multiple countries.
• Objective response rates of 30‑45% observed in new HER2‑positive indications.
• Potential European sales uplift estimated in the high‑hundreds of millions of euros.

Pulse Analysis

Enhertu’s expanded indication reflects a broader trend where antibody‑drug conjugates are moving from niche, late‑line settings into earlier lines of therapy. The drug’s ability to deliver a potent topoisomerase I inhibitor directly to HER2‑expressing cells gives it a pharmacologic edge that many competitors lack, especially in tumor types where HER2 expression is heterogeneous. This regulatory win could catalyze a wave of label extensions for other ADCs, prompting manufacturers to prioritize multi‑cancer development programs.

From a commercial perspective, AstraZeneca and Daiichi Sankyo stand to benefit from a synergistic partnership that leverages AstraZeneca’s extensive European sales network and Daiichi Sankyo’s manufacturing capabilities. The combined expertise reduces time‑to‑market and spreads financial risk, a model that may become more common as the ADC market matures. However, the partnership must navigate pricing pressures from health‑technology assessment bodies that are increasingly scrutinizing high‑cost oncology therapies.

Looking forward, the success of Enhertu’s broader rollout will hinge on the outcomes of ongoing Phase III studies in HER2‑low and HER2‑mutated cancers. Positive data could further erode the market share of traditional HER2 antibodies and cement ADCs as the preferred modality for HER2‑driven disease. Stakeholders should monitor the European Commission’s final approval timeline and the potential ripple effects on pipeline decisions across the oncology sector.